Clinical Trial Update: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene [Phase 3]

View source ↗

Summary

A Phase 3 gene therapy trial for X-linked retinitis pigmentosa caused by RPGR variants has completed, with Janssen providing the status update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinitis Pigmentosa

Drugs mentioned

• RPGR gene therapy

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: X-Linked Retinitis Pigmentosa | Phase 3 | Status: COMPLETED